Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series.

Autor:	Buness JG; Arizona College of Osteopathic Medicine, Midwestern University, Downers Grove, IL., Ali AH; Division of Hepatology, Mayo Clinic, Phoenix, AZ.; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO., Tabibian JH; Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Los Angeles, CA., Buness CW; National Patient Advocate Foundation, Arizona State University, Phoenix, AZ; and., Cox KL; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Stanford University, Palo Alto, CA., Lindor KD; Arizona College of Osteopathic Medicine, Midwestern University, Downers Grove, IL.; Division of Hepatology, Mayo Clinic, Phoenix, AZ.
Jazyk:	angličtina
Zdroj:	American journal of therapeutics [Am J Ther] 2022 Jul 01; Vol. 29 (4), pp. e437-e443. Date of Electronic Publication: 2022 Jul 01.
DOI:	10.1097/MJT.0000000000001065
Abstrakt:	Background: Primary sclerosing cholangitis (PSC) is linked to inflammatory bowel diseases (IBD). Evidence suggests an association between the gut microbiome and PSC. However, the putative relationship between exposure to antibiotics and onset of PSC has never been reported. We observed 3 cases in which patients without antecedent liver or bowel issues developed symptoms leading to diagnosis of IBD and subsequently PSC after being exposed to doxycycline. We aimed to identify, through the PSC Partners national patient registry, additional cases of PSC in which there is a temporal relationship between exposure to doxycycline and onset of PSC or PSC-IBD. Areas of Uncertainty: The etiopathogenesis of PSC remains an enigma. Data Sources: We collected data from patients with PSC and PSC-IBD in which there seemed to be a temporal relationship between exposure to doxycycline and PSC. Time from doxycycline exposure to: (1) onset of PSC or PSC-IBD symptoms and (2) diagnosis of PSC were documented for each patient. Descriptive statistical analyses were performed. Results: We identified 6 additional patients with PSC or PSC-IBD in whom there was a temporal relationship between exposure to doxycycline and onset of PSC or PSC-IBD. The median age of these 9 patients was 20 years, 6 were female, and 7 had ulcerative colitis. The median time from doxycycline exposure to onset of first symptoms was 3 months, and median time from doxycycline exposure to diagnosis of PSC was 15 months. Therapeutic Hypothesis: We describe 9 cases of PSC and PSC-IBD in which there seem to be a temporal relationship between exposure to doxycycline and onset of PSC. Competing Interests: The authors have no conflicts of interest to declare. (Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu